Global Cervical Cancer Vaccine Market Opportunities, 2020
Cervical cancer is mainly caused by Human Papilloma Virus (HPV) infection transmitted via sexual contact with an HPV-infected person. Two strains of HPV that are responsible for causing cervical cancer are HPV 16 and HPV 18. Cervical cancer vaccines are biological preparations that stimulate or strengthen a person's immune system against cancer. Increasing rate of unprotected sex, especially among adolescents, across various developed as well as developing regions, is resulting in growing incidences of cervical cancer, globally. As a result, an increasing number of people, especially females in the age group of 9-26 years, are opting for cervical cancer vaccines. Moreover, reduction in the number of recommended doses of HPV immunisation from three to two, which enhances the uptake of vaccine among a large adolescent female population, is anticipated to drive the global cervical cancer market during 2015 - 2020.
According to Pharmaion report, “Global Cervical Cancer Vaccine Market Opportunities, 2020”, global cervical cancer market is anticipated to cross US$ 1.6 billion by 2020 on account of increasing immunization programs for HPV vaccination, rising prevalence of cervical cancer and favorable government initiatives to increase disease awareness. However, the unavailability of HPV vaccines in some regions of the world, uncertain reimbursement rates, and changes in regulatory guidelines are hindering the growth of this market. In 2014, the United States was the largest consumer of cervical cancer vaccines, and the country is expected to continue its dominance through 2020 owing to the launch of a nine-valent HPV vaccine, Gardasil 9, in 2014 which protects against the infection of all 9 types of HPV, as compared to Gardasil that protects against only four HPV types. Majorly, two US FDA approved HPV vaccines, namely, Gardasil (Merck & Co., Inc.) and Cervarix (GlaxoSmithKline plc), are available across the globe. “Global Cervical Cancer Vaccine Market Opportunities, 2020” report elaborates following aspects related to global cervical cancer vaccine market:
The information contained in this report is based upon both primary and secondary sources. Primary research included interviews with cervical cancer vaccine producers and industry experts. Secondary research included an exhaustive search of relevant publications like company annual reports, financial reports and other proprietary databases.
According to Pharmaion report, “Global Cervical Cancer Vaccine Market Opportunities, 2020”, global cervical cancer market is anticipated to cross US$ 1.6 billion by 2020 on account of increasing immunization programs for HPV vaccination, rising prevalence of cervical cancer and favorable government initiatives to increase disease awareness. However, the unavailability of HPV vaccines in some regions of the world, uncertain reimbursement rates, and changes in regulatory guidelines are hindering the growth of this market. In 2014, the United States was the largest consumer of cervical cancer vaccines, and the country is expected to continue its dominance through 2020 owing to the launch of a nine-valent HPV vaccine, Gardasil 9, in 2014 which protects against the infection of all 9 types of HPV, as compared to Gardasil that protects against only four HPV types. Majorly, two US FDA approved HPV vaccines, namely, Gardasil (Merck & Co., Inc.) and Cervarix (GlaxoSmithKline plc), are available across the globe. “Global Cervical Cancer Vaccine Market Opportunities, 2020” report elaborates following aspects related to global cervical cancer vaccine market:
- Global Cervical Cancer Vaccine Market Size, Share & Forecast
- Segmental Analysis – By Region & By Company
- Policy & Regulatory Landscape
- Changing Market Trends & Emerging Opportunities
- Competitive Landscape & Strategic Recommendations
- To identify the on-going trends and anticipated growth in the next five years
- To gain competitive knowledge of leading market players
- To avail 10% customization in the report without any extra charges and get the research data or trends added in the report as per the buyer’s specific needs
The information contained in this report is based upon both primary and secondary sources. Primary research included interviews with cervical cancer vaccine producers and industry experts. Secondary research included an exhaustive search of relevant publications like company annual reports, financial reports and other proprietary databases.
1. PRODUCT OVERVIEW
2. ANALYST VIEW
3. RESEARCH METHODOLOGY
4. GLOBAL CERVICAL CANCER PATIENT EPIDEMIOLOGY
5. GLOBAL CERVICAL CANCER VACCINE MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Region (United States, European Union & ROW)
5.3. By Company (Merck & Co., Inc., GlaxoSmithKline plc & Xiamen Innovax Biotech Co., Ltd.)
6. UNITED STATES CERVICAL CANCER VACCINE MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.1.2. By Volume
6.2. Market Share & Forecast
6.2.1. By Company (Merck & Co., Inc. & GlaxoSmithKline plc)
6.3. US Cervical Cancer Patient Epidemiology
7. EUROPE CERVICAL CANCER VACCINE MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.1.2. By Volume
7.2. Market Share & Forecast
7.2.1. By Company (Sanofi Pasteur MSD & GlaxoSmithKline plc)
7.3. Europe Cervical Cancer Patient Epidemiology
8. ROW CERVICAL CANCER VACCINE MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Company (GlaxoSmithKline plc, Merck Sharpe & Dome and Xiamen Innovax Biotech Co., Ltd.)
9. MARKET DYNAMICS
9.1. Drivers
9.2. Challenges
10. MARKET TRENDS & DEVELOPMENTS
10.1. New Product Development
10.2. Patient Assistance Program
10.3. Reduced HPV Vaccine Dosage
10.4. Expanding Involvement of Pharmacists
11. COMPETITIVE LANDSCAPE
11.1. Merck & Co., Inc.
11.1.1. Company Overview
11.1.2. Regulatory Footprint: Gardasil
11.1.3. Clinical Highlights: Gardasil
11.2. GlaxoSmithKline plc
11.2.1. Company Overview
11.2.2. Regulatory Footprint: Cervarix
11.2.3. Clinical Highlights: Cervarix
11.3. Xiamen Innovax Biotech Co., Ltd.
12. STRATEGIC RECOMMENDATIONS
2. ANALYST VIEW
3. RESEARCH METHODOLOGY
4. GLOBAL CERVICAL CANCER PATIENT EPIDEMIOLOGY
5. GLOBAL CERVICAL CANCER VACCINE MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Region (United States, European Union & ROW)
5.3. By Company (Merck & Co., Inc., GlaxoSmithKline plc & Xiamen Innovax Biotech Co., Ltd.)
6. UNITED STATES CERVICAL CANCER VACCINE MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.1.2. By Volume
6.2. Market Share & Forecast
6.2.1. By Company (Merck & Co., Inc. & GlaxoSmithKline plc)
6.3. US Cervical Cancer Patient Epidemiology
7. EUROPE CERVICAL CANCER VACCINE MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.1.2. By Volume
7.2. Market Share & Forecast
7.2.1. By Company (Sanofi Pasteur MSD & GlaxoSmithKline plc)
7.3. Europe Cervical Cancer Patient Epidemiology
8. ROW CERVICAL CANCER VACCINE MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Company (GlaxoSmithKline plc, Merck Sharpe & Dome and Xiamen Innovax Biotech Co., Ltd.)
9. MARKET DYNAMICS
9.1. Drivers
9.2. Challenges
10. MARKET TRENDS & DEVELOPMENTS
10.1. New Product Development
10.2. Patient Assistance Program
10.3. Reduced HPV Vaccine Dosage
10.4. Expanding Involvement of Pharmacists
11. COMPETITIVE LANDSCAPE
11.1. Merck & Co., Inc.
11.1.1. Company Overview
11.1.2. Regulatory Footprint: Gardasil
11.1.3. Clinical Highlights: Gardasil
11.2. GlaxoSmithKline plc
11.2.1. Company Overview
11.2.2. Regulatory Footprint: Cervarix
11.2.3. Clinical Highlights: Cervarix
11.3. Xiamen Innovax Biotech Co., Ltd.
12. STRATEGIC RECOMMENDATIONS
LIST OF TABLES
Table 1: Process of Development of Cervical Cancer after an HPV Infection
Table 2: Global HPV Vaccines and their HPV Types
Table 3: European Union Recommended HPV Immunization, By Country, By Age
Table 4: Partial List of HPV Vaccination Practices across European Union
Table 5: Cervarix and Gardasil Prices offered by GAVI, By Dose, By Year
Table 6: Cervical Cancer Vaccine in Pipeline
Table 7: Europe Two-dose HPV Vaccines Schedule Marketing Authorization, By Year, By Age Group
Table 8: Countries with Regulatory Approval of Gardasil
Table 9: Key Results from Phase III Trials of Gardasil Vaccine
Table 10: Key Results from Phase III Trials of Cervarix Vaccine
Table 1: Process of Development of Cervical Cancer after an HPV Infection
Table 2: Global HPV Vaccines and their HPV Types
Table 3: European Union Recommended HPV Immunization, By Country, By Age
Table 4: Partial List of HPV Vaccination Practices across European Union
Table 5: Cervarix and Gardasil Prices offered by GAVI, By Dose, By Year
Table 6: Cervical Cancer Vaccine in Pipeline
Table 7: Europe Two-dose HPV Vaccines Schedule Marketing Authorization, By Year, By Age Group
Table 8: Countries with Regulatory Approval of Gardasil
Table 9: Key Results from Phase III Trials of Gardasil Vaccine
Table 10: Key Results from Phase III Trials of Cervarix Vaccine
LIST OF FIGURES
Figure 1: Global Estimated Incidence and 5-Year Prevalence of Cancer of Cervix Uteri, By Number of Cases, 2012
Figure 2: Estimated Incidence of Cancer of Cervix Uteri, By Region, By Number of Cases, 2012
Figure 3: Global Cervical Cancer Vaccine Market Size, By Value, 2010-2020F (USD Million)
Figure 4: Global Cervical Cancer Vaccine Market Share, By Region, By Value, 2010-2020F
Figure 5: Global Cervical Cancer Vaccine Market Share, By Company, By Volume, 2010-2020F
Figure 6: United States Cervical Cancer Vaccine Market Size, By Value (USD Million), By Volume (‘000 Doses), 2010-2020F
Figure 7: United States Percentage of 13 to 17 Year-old Girls Completing HPV Vaccine 3 Dose, 2012
Figure 8: United States Percentage of 13 to 17 Year-old Girls Completing HPV Vaccine 3 Dose, 2014
Figure 9: United States Gardasil and Cervarix Vaccine for Children, Average Selling Price (ASP), 2010-2014, (USD/Dose)
Figure 10: United States Gardasil and Cervarix Vaccine for Adults Average Selling Price (ASP), 2010-2014, (USD/Dose)
Figure 11: United States Cervical Cancer Vaccine Market Share, By Company, By Value, 2010-2020F
Figure 12: United States High School Female Students Sexual Dating Violence, By Percentage, By Grade, 2013
Figure 13: United Sates Estimated Incidence of Cervix Uteri Cancer and Mortality, By Number of Cases, 2012, 2015E & 2020F
Figure 14: European Union Cervical Cancer Vaccine Market Size, By Value (USD Million), By Volume (‘000 Doses), 2010-2020F
Figure 15: Germany Cervix Uteri Cancer Incidence and Mortality, 2012, 2015E & 2020F
Figure 16: Germany Cervix Uteri Cancer, 1-year Prevalence, 3-year Prevalence & 5-year Prevalence
Figure 17: Italy Cervix Uteri Cancer Incidence and Mortality, 2012, 2015E & 2020F
Figure 18: Italy Cervix Uteri Cancer, 1-year Prevalence, 3-year Prevalence & 5-year Prevalence
Figure 19: France Cervix Uteri Cancer Incidence and Mortality, 2012, 2015E & 2020F
Figure 20: France Cervix Uteri Cancer, 1-year Prevalence, 3-year Prevalence & 5-year Prevalence
Figure 21: United Kingdom Cervix Uteri Cancer Incidence and Mortality, 2012, 2015E & 2020F
Figure 22: United Kingdom Cervix Uteri Cancer, 1-year Prevalence, 3-year Prevalence and 5-year Prevalence
Figure 23: European Union Cervical Cancer Vaccine Market Share, By Company, By Value, 2010-2020F
Figure 24: European Union Cervix Uteri Cancer Incidence and Mortality, By Number of Cases, 2012, 2015E & 2020F
Figure 25: Rest of the World Cervical Cancer Vaccine Market Size, By Value (USD Million), 2010-2020F
Figure 26: Japan Major Events Related to HPV Vaccines, 2010-2013
Figure 27: Japan Major Events Related to HPV Vaccines, 2013-2015
Figure 28: Australia HPV 3 Dose Vaccine Coverage for Females of Age 15 years, By State, By Number, 2014
Figure 29: Australia HPV 3-Dose Vaccine Coverage for Females of Age 15 years, By State, By Percentage, 2012-14
Figure 30: ROW Cervical Cancer Vaccine Market Share, By Region, By Value, 2010-2020F
Figure 31: Middle East and North Africa Estimated Incidence of Cancer of Cervix Uteri, By Number of Cases, 2012, 2015E & 2020F
COMPANIES MENTIONED
1. Merck & Co., Inc.
2. GlaxoSmithKline plc
3. Xiamen Innovax Biotech Co., Ltd.
Figure 1: Global Estimated Incidence and 5-Year Prevalence of Cancer of Cervix Uteri, By Number of Cases, 2012
Figure 2: Estimated Incidence of Cancer of Cervix Uteri, By Region, By Number of Cases, 2012
Figure 3: Global Cervical Cancer Vaccine Market Size, By Value, 2010-2020F (USD Million)
Figure 4: Global Cervical Cancer Vaccine Market Share, By Region, By Value, 2010-2020F
Figure 5: Global Cervical Cancer Vaccine Market Share, By Company, By Volume, 2010-2020F
Figure 6: United States Cervical Cancer Vaccine Market Size, By Value (USD Million), By Volume (‘000 Doses), 2010-2020F
Figure 7: United States Percentage of 13 to 17 Year-old Girls Completing HPV Vaccine 3 Dose, 2012
Figure 8: United States Percentage of 13 to 17 Year-old Girls Completing HPV Vaccine 3 Dose, 2014
Figure 9: United States Gardasil and Cervarix Vaccine for Children, Average Selling Price (ASP), 2010-2014, (USD/Dose)
Figure 10: United States Gardasil and Cervarix Vaccine for Adults Average Selling Price (ASP), 2010-2014, (USD/Dose)
Figure 11: United States Cervical Cancer Vaccine Market Share, By Company, By Value, 2010-2020F
Figure 12: United States High School Female Students Sexual Dating Violence, By Percentage, By Grade, 2013
Figure 13: United Sates Estimated Incidence of Cervix Uteri Cancer and Mortality, By Number of Cases, 2012, 2015E & 2020F
Figure 14: European Union Cervical Cancer Vaccine Market Size, By Value (USD Million), By Volume (‘000 Doses), 2010-2020F
Figure 15: Germany Cervix Uteri Cancer Incidence and Mortality, 2012, 2015E & 2020F
Figure 16: Germany Cervix Uteri Cancer, 1-year Prevalence, 3-year Prevalence & 5-year Prevalence
Figure 17: Italy Cervix Uteri Cancer Incidence and Mortality, 2012, 2015E & 2020F
Figure 18: Italy Cervix Uteri Cancer, 1-year Prevalence, 3-year Prevalence & 5-year Prevalence
Figure 19: France Cervix Uteri Cancer Incidence and Mortality, 2012, 2015E & 2020F
Figure 20: France Cervix Uteri Cancer, 1-year Prevalence, 3-year Prevalence & 5-year Prevalence
Figure 21: United Kingdom Cervix Uteri Cancer Incidence and Mortality, 2012, 2015E & 2020F
Figure 22: United Kingdom Cervix Uteri Cancer, 1-year Prevalence, 3-year Prevalence and 5-year Prevalence
Figure 23: European Union Cervical Cancer Vaccine Market Share, By Company, By Value, 2010-2020F
Figure 24: European Union Cervix Uteri Cancer Incidence and Mortality, By Number of Cases, 2012, 2015E & 2020F
Figure 25: Rest of the World Cervical Cancer Vaccine Market Size, By Value (USD Million), 2010-2020F
Figure 26: Japan Major Events Related to HPV Vaccines, 2010-2013
Figure 27: Japan Major Events Related to HPV Vaccines, 2013-2015
Figure 28: Australia HPV 3 Dose Vaccine Coverage for Females of Age 15 years, By State, By Number, 2014
Figure 29: Australia HPV 3-Dose Vaccine Coverage for Females of Age 15 years, By State, By Percentage, 2012-14
Figure 30: ROW Cervical Cancer Vaccine Market Share, By Region, By Value, 2010-2020F
Figure 31: Middle East and North Africa Estimated Incidence of Cancer of Cervix Uteri, By Number of Cases, 2012, 2015E & 2020F
COMPANIES MENTIONED
1. Merck & Co., Inc.
2. GlaxoSmithKline plc
3. Xiamen Innovax Biotech Co., Ltd.
